hearing_witnesses
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
8 rows where package_id = "CHRG-109hhrg29726" sorted by name
This data as json, CSV (advanced)
Suggested facets: title
organization 8
- 000 per dose. The difference is so staggering...."4 Without some form of government support for the ``valley of death, '' perhaps in the form of grants, contracts, or significant milestone payments such as the Department of Defense uses in the acquisition of complex weapons systems, few companies will be able to secure outside financing or invest their own capital in countermeasure development. Government-funded basic research is an essential part of biodefense strategy 1
- 2003, was proposed to accelerate the process of research, development, purchase, 1
- 2004. Project BioShield enables the Government to develop, procure, and make available countermeasures to chemical, biological, radiological, and nuclear agents for use in a public health emergency that affects national security. Pharmaceutical research and development historically has focused on development of products likely to attract significant commercial interest. Many countermeasures for potential agents of terrorism realistically h 1
- a number of criticisms hav 1
- a radiological/nuclear product and that, to my understanding has been delivered. That is correct, I am told. But we need to speed up this process. What we need to do in terms of our efforts is first, we have got to develop a broad strategic plan here on moving forward. Instead of individual material threat assessments-- MS. ESHOO. So this is not part of our plan? MR. AZ 1
- negotiations are underway for procuring 200, 000 doses of botulinum antitoxin. The experience implementing BioShield has highlighted challenges. The potential payoff for a breakthrough in medical countermeasures against chemical, biological, and nuclear/radiological, CBRN threats, is modest when compared with other drugs. For example, the global market for just one cholesterol-lowering ag 1
- only 5 make it to clinical trials and only one of these, on average, will become a licensed product.2 The lack of support from the US government during the crucial intermediate stages of development results in premature failures of potential countermeasures as biopharma companies struggle to maintain operations through long periods of uncertainty without outside support. The priorities of the private capital markets, instead of the priorities of gove 1
- sir. MR. ROGERS. And for naturally occurring. So it wouldn't have the same target set, maybe, as a BioShield-- MR. AZAR. No, that $160 million is actually focused on chemical, bio 1
| id | package_id | name ▼ | title | organization | organization_normalized | location |
|---|---|---|---|---|---|---|
| 24354 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | $160 million for advanced research and development. Yes budget | and radiological/nuclear advanced research and development. It is meant to be in league with the implementation of the BioShield purchasing. It is part of the pulling effort there to get these products closer to the BioShield contracting point. MR. ROGER | sir. MR. ROGERS. And for naturally occurring. So it wouldn't have the same target set, maybe, as a BioShield-- MR. AZAR. No, that $160 million is actually focused on chemical, bio | SIR. MR. ROGERS. AND FOR NATURALLY OCCURRING. SO IT WOULDN'T HAVE THE SAME TARGET SET, MAYBE, AS A BIOSHIELD-- MR. AZAR. NO, THAT $160 MILLION IS ACTUALLY FOCUSED ON CHEMICAL, BIO | |
| 24352 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | and it was signed into law by President Bush on July 21 | 2004. Project BioShield enables the Government to develop, procure, and make available countermeasures to chemical, biological, radiological, and nuclear agents for use in a public health emergency that affects national security. Pharmaceutical research and development historically has focused on development of products likely to attract significant commercial interest. Many countermeasures for potential agents of terrorism realistically h | 2004. PROJECT BIOSHIELD ENABLES THE GOVERNMENT TO DEVELOP, PROCURE, AND MAKE AVAILABLE COUNTERMEASURES TO CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR AGENTS FOR USE IN A PUBLIC HEALTH EMERGENCY THAT AFFECTS NATIONAL SECURITY. PHARMACEUTICAL RESEARCH AND DEVELOPMENT HISTORICALLY HAS FOCUSED ON DEVELOPMENT OF PRODUCTS LIKELY TO ATTRACT SIGNIFICANT COMMERCIAL INTEREST. MANY COUNTERMEASURES FOR POTENTIAL AGENTS OF TERRORISM REALISTICALLY H | ||
| 24355 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | drug ``candidates'' identified by scientists | only 5 make it to clinical trials and only one of these, on average, will become a licensed product.2 The lack of support from the US government during the crucial intermediate stages of development results in premature failures of potential countermeasures as biopharma companies struggle to maintain operations through long periods of uncertainty without outside support. The priorities of the private capital markets, instead of the priorities of gove | ONLY 5 MAKE IT TO CLINICAL TRIALS AND ONLY ONE OF THESE, ON AVERAGE, WILL BECOME A LICENSED PRODUCT.2 THE LACK OF SUPPORT FROM THE US GOVERNMENT DURING THE CRUCIAL INTERMEDIATE STAGES OF DEVELOPMENT RESULTS IN PREMATURE FAILURES OF POTENTIAL COUNTERMEASURES AS BIOPHARMA COMPANIES STRUGGLE TO MAINTAIN OPERATIONS THROUGH LONG PERIODS OF UNCERTAINTY WITHOUT OUTSIDE SUPPORT. THE PRIORITIES OF THE PRIVATE CAPITAL MARKETS, INSTEAD OF THE PRIORITIES OF GOVE | ||
| 24353 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | for additional pediatric liquid potassium iodide and that is still pending delivery. And then we have the chelating agent DTPA | a radiological/nuclear product and that, to my understanding has been delivered. That is correct, I am told. But we need to speed up this process. What we need to do in terms of our efforts is first, we have got to develop a broad strategic plan here on moving forward. Instead of individual material threat assessments-- MS. ESHOO. So this is not part of our plan? MR. AZ | A RADIOLOGICAL/NUCLEAR PRODUCT AND THAT, TO MY UNDERSTANDING HAS BEEN DELIVERED. THAT IS CORRECT, I AM TOLD. BUT WE NEED TO SPEED UP THIS PROCESS. WHAT WE NEED TO DO IN TERMS OF OUR EFFORTS IS FIRST, WE HAVE GOT TO DEVELOP A BROAD STRATEGIC PLAN HERE ON MOVING FORWARD. INSTEAD OF INDIVIDUAL MATERIAL THREAT ASSESSMENTS-- MS. ESHOO. SO THIS IS NOT PART OF OUR PLAN? MR. AZ | ||
| 24349 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | for participating in today's hearing and I know the subcommittee is eager to hear your testimony. Nearly two years ago Congress passed the Project BioShield Act with tremendous bipartisan support. Democrats and Republicans worked together to establish a process that would help our Nation respond to bioterrorism threats and attacks. Today's hearing will give us an opportunity to assess how well the program is working to meet this important goal. Since going into effect | a number of criticisms hav | A NUMBER OF CRITICISMS HAV | ||
| 24350 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | million doses of a next generation attenuated smallpox vaccine called modified vaccinia Ankara. Additionally | negotiations are underway for procuring 200, 000 doses of botulinum antitoxin. The experience implementing BioShield has highlighted challenges. The potential payoff for a breakthrough in medical countermeasures against chemical, biological, and nuclear/radiological, CBRN threats, is modest when compared with other drugs. For example, the global market for just one cholesterol-lowering ag | NEGOTIATIONS ARE UNDERWAY FOR PROCURING 200, 000 DOSES OF BOTULINUM ANTITOXIN. THE EXPERIENCE IMPLEMENTING BIOSHIELD HAS HIGHLIGHTED CHALLENGES. THE POTENTIAL PAYOFF FOR A BREAKTHROUGH IN MEDICAL COUNTERMEASURES AGAINST CHEMICAL, BIOLOGICAL, AND NUCLEAR/RADIOLOGICAL, CBRN THREATS, IS MODEST WHEN COMPARED WITH OTHER DRUGS. FOR EXAMPLE, THE GLOBAL MARKET FOR JUST ONE CHOLESTEROL-LOWERING AG | ||
| 24351 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | of the Union address on January 28 | and availability of effective countermeasures against agents of bioterror. Then HHS Secretary Tommy Thompson and Department of Homeland Security (DHS) Secretary Tom Ridge jointly transmitted the ``Project BioShield Act of 2003'' to Congress on February 26 | 2003, was proposed to accelerate the process of research, development, purchase, | 2003, WAS PROPOSED TO ACCELERATE THE PROCESS OF RESEARCH, DEVELOPMENT, PURCHASE, | |
| 24356 | PROJECT BIOSHIELD REAUTHORIZATION ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED NINTH CONGRESS SECOND SESSION CHRG-109hhrg29726 | you can charge $40 months | 000 per dose. The difference is so staggering...."4 Without some form of government support for the ``valley of death, '' perhaps in the form of grants, contracts, or significant milestone payments such as the Department of Defense uses in the acquisition of complex weapons systems, few companies will be able to secure outside financing or invest their own capital in countermeasure development. Government-funded basic research is an essential part of biodefense strategy | 000 PER DOSE. THE DIFFERENCE IS SO STAGGERING...."4 WITHOUT SOME FORM OF GOVERNMENT SUPPORT FOR THE ``VALLEY OF DEATH, '' PERHAPS IN THE FORM OF GRANTS, CONTRACTS, OR SIGNIFICANT MILESTONE PAYMENTS SUCH AS THE DEPARTMENT OF DEFENSE USES IN THE ACQUISITION OF COMPLEX WEAPONS SYSTEMS, FEW COMPANIES WILL BE ABLE TO SECURE OUTSIDE FINANCING OR INVEST THEIR OWN CAPITAL IN COUNTERMEASURE DEVELOPMENT. GOVERNMENT-FUNDED BASIC RESEARCH IS AN ESSENTIAL PART OF BIODEFENSE STRATEGY |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE hearing_witnesses (
id INTEGER PRIMARY KEY AUTOINCREMENT,
package_id TEXT NOT NULL REFERENCES hearings(package_id),
name TEXT,
title TEXT,
organization TEXT,
organization_normalized TEXT,
location TEXT
);
CREATE INDEX idx_hw_package ON hearing_witnesses(package_id);
CREATE INDEX idx_hw_name ON hearing_witnesses(name);
CREATE INDEX idx_hw_org ON hearing_witnesses(organization) WHERE organization IS NOT NULL AND organization != '';
CREATE INDEX idx_hw_org_norm ON hearing_witnesses(organization_normalized) WHERE organization_normalized IS NOT NULL;